Breast and Ovarian Cancer Program (BOCP) The mission of the Breast and Ovarian Cancer Program (BOCP), a newly established Program being proposed in this UPCI Cancer Center Support Grant renewal, is to reduce the incidence and death from women's cancer with a focus on breast and ovarian malignancies. This mission is achieved through the development and fostering of basic, translational, and clinical research in breast and ovarian cancer and aimed at translating novel discoveries into improved patient care. The BOCP has four main research themes: 1) basic cancer biology, 2) diagnostic and prognostic markers, 3) prevention, and 4) molecular therapeutics. The BOCP specific aims are to: 1) investigate mechanisms of cancer initiation and progression, 2) identify and validate new diagnostic and prognostic markers, 3) examine the role of tumor evolution and heterogeneity in progression and response to therapy, 4) discover the phenotypic and genotypic dependencies of metastatic cancer, and 5) translate knowledge of the biology into personalized prevention and treatment. The BOCP has 42 members representing 12 academic departments and 3 schools of the University of Pittsburgh. Based upon a retrospective analysis of historical data from January 2010 to April 2014, BOCP members authored or co- authored 517 cancer-related publications, of which 31% resulted from intra-programmatic and 30% from inter- programmatic collaborations. Approximately 54% of the papers represent collaborations with external investigators. Research in the BOCP is supported by an NCI Specialized Program of Research Excellence (SPORE) in Ovarian Cancer shared with Roswell Park Cancer Institute (RPCI), as well as individual federal grants, foundation awards, and philanthropy. BOCP members currently receive a total of $8.2 M in annual direct funding, including $2.6 M from the NCI and $2.1 M in other peer-reviewed grant support. A highly collaborative and interactive group, BOCP members meet regularly at work-in-progress meetings, journal clubs, and a yearly retreat. In addition, the BOCP forges relationships with other programs to enhance the multi-disciplinary nature of breast and ovarian cancer research at UPCI. UPCI support, including Clinical Protocol and Data Management and Shared Resources, specifically the Animal Facility, Biostatistics Facility, Cancer Bioinformatics Services, Cancer Genomics Facility, Cancer Pharmacokinetics and Pharmacodynamics Facility, Cancer Proteomics Facility, Cell and Tissue Imaging Facility, Chemical Biology Facility, Cytometry Facility, Immunological Monitoring and Cellular Products Laboratory, In Vivo Imaging Facility, Investigational Drug Services, and Tissue and Research Pathology Services facilitates and enhances BOCP research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Samanta, Suman K; Lee, Joomin; Hahm, Eun-Ryeong et al. (2018) Peptidyl-prolyl cis/trans isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells. Mol Carcinog 57:936-946
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Persky, Michael J; Albergotti, William G; Rath, Tanya J et al. (2018) Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 158:660-666
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Zang, Yachen; Pascal, Laura E; Zhou, Yibin et al. (2018) ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells. Cancer Lett 415:198-207
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650

Showing the most recent 10 out of 1187 publications